He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.
View all episodes
By BiotechTV
5
44 ratings
He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.
30,632 Listeners
1,867 Listeners
1,087 Listeners
325 Listeners
6,057 Listeners
60 Listeners
9,844 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
499 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners